In this webinar, you will learn: How to select the appropriate bispecific antibody format based on your target and functional intent. How to apply the various manufacturing and protein engineering approaches to overcome bispecific complexity. How high-confidence monoclonal antibody sequencing enables reproducible bispecific design. Building Bispecific Antibodies with Confidence Bispecific [...]
In this webinar, you will learn: About paratope-centered patenting as a way to build stronger, structurally defined claims that withstand enablement and design-around challenges. How evolving case law, USPTO guidance, and antibody characterization tools can open new avenues for securing robust protection for therapeutic antibodies. Experimental strategies for resolving epitope and paratope [...]
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Our client is a biotechnology company developing therapeutics that target cancer-specific carbohydrate antigens on the surface of tumour cells.
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications